GNBT News and Press, Generex Biotechnology From 08/13/20

A Hybrid Approach for Vascular Control and Repair of an Expanding Iatrogenic Femoral Artery Pseudoaneurysm J. Gorecka, J.F Chen, S. Shah, A. Dardik, R.J Guzman, N. Nassiri, Journal of Vascular Surgery Cases and Innovative Techniques (July 18, 2020) , doi: https://doi.org/10.1016/j.jv...

Ii-Key-SARS-CoV-2 vaccine progress Ii-Key-H1 Swine flu vaccine opportunity SEC Filings and plans for listing on a national exchange MIRAMAR, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology ( NGIO ) today announced that it will hold an investor conference call on Thur...

Telemedicine & Remote Patient Monitoring Partnership Arizona MSO/HMO update AltuCell acquisition update MIRAMAR, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that it will hold an investor conference ...

MIRAMAR, Fla., July 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the FDA has accepted their pre-IND briefing package for the Ii-Key-SARS-CoV-2 coronavirus prophylactic ...

Generex Biotechnology ( OTCQB:GNBT +2.2% )  submits a pre-IND briefing package to FDA for guidance on the Phase 1/2 trial protocol and clinical development plan for the Ii-Key-SARS-CoV-2 prophylactic vaccine. More news on: Generex Biotechnology Corporation, Healthcare stocks news, ...

Submitted Pre-IND briefing package outlining proposed clinical development program for Ii-Key-SARS-CoV-2 prophylactic peptide vaccine against the coronavirus pandemic Final protocol submitted with package to conduct a Phase I/II human clinical trial MIRAMAR, Fla., July 20, 2020 (GLOBE...

NuGenerex Immuno-Oncology, a 91% subsidiary of Generex Biotechnology Corporation (GNBT:OTCQB) announces first financing in preparation for public listing NuGenerex Immuno-Oncology is developing immunotherapeutic Ii-Key peptide vaccines for cancer and infectious diseases MIRAMAR, Fla.,...

MIRAMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for today’s investor conference call on Friday July 10 th 2020 at 4:15 PM Eastern time . The access information for the investor conf...

NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to 2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and immunologic data for Ii-Key-H1 peptide vaccine Ii-Key-H1 peptide sequence is 100% homologous in previous pandemic influenza threats ...

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO is now a stand-alone public company with plans to list shares on Nasdaq MIRAMAR, Fla., June 26, 2020...